{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:40:40Z","timestamp":1786117240060,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["advancessurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.yasu.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:09:27Z","timestamp":1777892967000},"page":"85-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Therapy for Melanoma"],"prefix":"10.1016","volume":"60","author":[{"given":"Margaret H.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"DeLaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yasu.2026.03.005_bib1","series-title":"Drugs approved for Melanoma","author":"Institute","year":"2024"},{"key":"10.1016\/j.yasu.2026.03.005_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jso.26229","article-title":"Neoadjuvant immunotherapy for melanoma","volume":"123","author":"Lee","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":", Blank CU: personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib8","doi-asserted-by":"crossref","first-page":"TPS9605","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605","article-title":"The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma","volume":"40","author":"Lucas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib9","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA2","article-title":"Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: the phase 3 NADINA trial","volume":"42","author":"Blank","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib10","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB Melanoma with high-dose interferon Alfa-2b induces objective tumor regression in Association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J Clin Oncol"},{"issue":"112","key":"10.1016\/j.yasu.2026.03.005_bib11","article-title":"Neoadjuvant ipilimumab (3 mg\/kg or 10 mg\/kg) and high dose IFN-\u03b12b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.yasu.2026.03.005_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.yasu.2026.03.005_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9504","article-title":"Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): primary analysis","volume":"43","author":"Mooradian","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib15","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2025.43.16_suppl.9502","article-title":"Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB\/C melanoma","volume":"43","author":"Miura","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib16","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1200\/JCO.2025.43.16_suppl.9512","article-title":"Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II\/III acral melanoma: the CAP 03-NEO trial","volume":"43","author":"Mao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable stage III melanoma: the phase II NeoACTIVATE trial","volume":"15","author":"Hieken","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.yasu.2026.03.005_bib20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB\u2013IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib21","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1200\/JCO.2023.41.16_suppl.9546","article-title":"Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB\/C\/D-IV M1a) melanoma with injectable disease: NIVEC trial","volume":"41","author":"Zijlker","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib22","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.yasu.2026.03.005_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.yasu.2026.03.005_bib24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Long GV: five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11912-023-01369-6","article-title":"Neoadjuvant therapy in Melanoma: where are we now?","volume":"25","author":"Saad","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.yasu.2026.03.005_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1615\/CritRevOncog.2016014729","article-title":"Metastasectomy for stage IV melanoma in the era of effective systemic agents","volume":"21","author":"Ollila","year":"2016","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.yasu.2026.03.005_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib28","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.yasu.2026.03.005_bib29","series-title":"Adjuvant nivolumab or ipilimumab + nivolumab determined by pathological response to A single dose of neoadjvuant nivolumab","year":"2020"},{"key":"10.1016\/j.yasu.2026.03.005_bib30","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Karagiannis SN: combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.yasu.2026.03.005_bib31","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.yasu.2026.03.005_bib32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.amjsurg.2015.08.014","article-title":"Risk factors associated with lymphedema after lymph node dissection in melanoma patients","volume":"210","author":"Friedman","year":"2015","journal-title":"Am J Surg"},{"key":"10.1016\/j.yasu.2026.03.005_bib33","doi-asserted-by":"crossref","first-page":"e1306","DOI":"10.1097\/SLA.0000000000005459","article-title":"Multicenter experience with neoadjuvant therapy in melanoma highlights heterogeneity in contemporary practice","volume":"277","author":"Rhodin","year":"2023","journal-title":"Ann Surg"}],"container-title":["Advances in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341126000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065341126000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:26:41Z","timestamp":1786022801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065341126000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0065341126000059"],"URL":"https:\/\/doi.org\/10.1016\/j.yasu.2026.03.005","relation":{},"ISSN":["0065-3411"],"issn-type":[{"value":"0065-3411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Therapy for Melanoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yasu.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}